<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0011010'>Chronic</z:hpo> inflammatory <z:e sem="disease" ids="C0035435" disease_type="Disease or Syndrome" abbrv="">rheumatic diseases</z:e> lead to increased prevalence of <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>However, this early and <z:hpo ids='HP_0004943'>accelerated atherosclerosis</z:hpo> cannot be explained by traditional <z:e sem="disease" ids="C0850624" disease_type="Disease or Syndrome" abbrv="">cardiovascular risk factors</z:e> alone </plain></SENT>
<SENT sid="2" pm="."><plain>The permanent overexpression of cellular <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecules and pro-inflammatory cytokines in <z:hpo ids='HP_0011010'>chronic</z:hpo> inflammatory conditions may participate in <z:hpo ids='HP_0004943'>accelerated atherosclerosis</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Visfatin, a novel adipocytokine, has a potential insulin-like action and pro-inflammatory effects </plain></SENT>
<SENT sid="4" pm="."><plain>Therefore, the aim of the study was to determine serum visfatin level and its association with common carotid intima-media thickness (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IMT</z:e>), which is a predictor of <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo>, in patients with <z:hpo ids='HP_0001370'>rheumatoid arthritis</z:hpo> (RA), <z:hpo ids='HP_0002725'>systemic lupus erythematosus</z:hpo> (SLE), systemic <z:mp ids='MP_0000612'>sclerosis</z:mp> (SSc), and <z:chebi fb="6" ids="22696">Beh</z:chebi>çet's disease (BD) </plain></SENT>
<SENT sid="5" pm="."><plain>The study involved 29 RA, 26 SLE, 25 SSc, 30 BD patients, and 29 healthy controls (HC) </plain></SENT>
<SENT sid="6" pm="."><plain>Serum levels of TNF-α, IL-6, and visfatin were analyzed using enzyme-linked immunosorbent assay method and homeostasis model assessment for <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> (HOMA-IR) indexes, and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IMTs</z:e> were determined </plain></SENT>
<SENT sid="7" pm="."><plain>Serum visfatin level was higher in the RA group than <z:hpo ids='HP_0000001'>all</z:hpo> the other groups </plain></SENT>
<SENT sid="8" pm="."><plain>In addition, visfatin level was higher in the active BD subgroup than the inactive BD subgroup </plain></SENT>
<SENT sid="9" pm="."><plain>In the study groups, visfatin levels were not correlated with HOMA-IR indexes and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IMTs</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>Whereas visfatin serum concentration was not associated with <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> and carotid <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> in selected <z:e sem="disease" ids="C0035435" disease_type="Disease or Syndrome" abbrv="">rheumatic diseases</z:e>, it was higher in the RA and active BD groups, but not in the SLE and SSc groups </plain></SENT>
<SENT sid="11" pm="."><plain>Visfatin levels may be associated with Th1/Th2 balance </plain></SENT>
<SENT sid="12" pm="."><plain>Further studies are needed for more precise elucidation of the pro-inflammatory activities of visfatin </plain></SENT>
</text></document>